^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:thalidomide (TNF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BMC Cancer
    Title:

    Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

    Published date:
    10/14/2023
    Excerpt:
    Aponermin plus thalidomide and dexamethasone significantly improved PFS, OS and ORR with manageable side effects in RRMM patients who had received at least two prior therapies. These results support the use of aponermin, thalidomide, and dexamethasone as a treatment option for RRMM patients.
    Secondary therapy:
    dexamethasone
    DOI:
    10.1186/s12885-023-11489-8
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

    Excerpt:
    The response rate with thalidomide plus dexamethasone was significantly higher than with dexamethasone alone (63% v 41%, respectively; P = .0017)….Thalidomide plus dexamethasone demonstrates significantly superior response rates in newly diagnosed myeloma compared with dexamethasone alone.
    Secondary therapy:
    dexamethasone
    DOI:
    10.1200/JCO.2005.03.0221